Sandy Munro, PhD, Senior Vice-President – Pharmaceutical Development, has been at Vectura since 2008 in a variety of pharmaceutical development leadership roles focused on dry powder inhaler (DPI) and smart nebuliser product development, as well as leading novel inhaled technology development programmes and defining the company’s technology strategy.

Prior to joining Vectura, Dr Munro enjoyed a 20-year career at GSK, joining as an analytical scientist in 1987, progressing through a number of roles to become GSK’s Global Director of Inhaled Science and Technology. During his time there, he played a leading role in the transition from chlorofluorocarbon (CFC) to hydrofluoroalkane (HFA) propellants for GSK’s pressurised metered dose inhaler (pMDI) products, was a long-term member of the leadership team for GSK’s inhaled product development programmes and led a variety of projects in next-generation inhaler systems development, including novel excipients for pMDIs and DPIs.

He holds a chemistry degree from the University of Edinburgh (UK) and a PhD in synthetic organic chemistry from the University of East Anglia (UK). He is also an honorary life member of The Aerosol Society of Great Britain.